Skip to main content
Equibles
SHC logo

SHC · Sotera Health Co

Track SHC — free

Use SHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.61 +0.31 (+1.90%) At close · Nov 13
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$4.74B
Shares
285.63M
Volume · Nov 13 2.65M Avg daily vol (3M) 2.3M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.61 Open$16.39 Day$16.15–16.65 52W close$13.13–19.57 Avg vol 30d2.4M Short int16.4M · 5.8% of shares · 7.5d Short vol75% Last earningsNov 3, 2026 DataNov 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Next earnings call
Feb 23, 2027 Est · unconfirmed · in 14 wks
Q3 2026 earnings call transcript
call held Nov 3, 2026
Play latest call

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 7.7%; nine-month net income reaches $138.6 million

Sotera Health Co reported revenue of $926.3 million, up 7.7%, and net income of $138.6 million, up from $43.1 million, for the nine months ended September 30, 2026.

Revenue $324.89M ▲ 4.4% Net income $58.39M ▲ 20.6% Diluted EPS $0.20 ▲ 17.6%
Read from the MD&A section
2 source passages
Net revenues were $926.3 million for the nine months ended September 30, 2026, an increase of $66.1 million, or 7.7%, as compared to the nine months ended September 30, 2025. Net income for the nine months ended September 30, 2026 was $138.6 million, as compared to net income of $43.1 million for the nine months ended September 30, 2025 due to the factors described above. Open the document at this passage
Nov 3
Earnings call
Reaffirms 2026 outlook as European medical device demand softens

Sotera Health reaffirmed its 2026 outlook while citing European medical device softness at Sterigenics, projecting revenue of $1.233 billion to $1.250 billion, adjusted EBITDA of $632 million to $641 million, and adjusted EPS of $0.95 to $1.01.

4 source passages
Thanks for your continued interest in Sotera Health. We started seeing some of the softness kind of mid to late Q3, and primarily that softness came from our European customers. we are maintaining our 2026 revenue outlook of 5.25% to 6.75% constant currency growth, with reported revenue in the range of $1.233 billion to $1.250 billion. We also remain confident in our full-year adjusted EBITDA outlook of 5.75% to 7.25% constant currency growth. with adjusted EBITDA in the range of $632 million to $641 million. we expect to remain on track to deliver adjusted EPS of $0.95 to $1.01 for diluted share in 2026. Open the document at this passage
Nov 3
Current report 8-K
Third-Quarter Growth Supports Reaffirmed 2026 Outlook

Sotera Health reported Q3 2026 net revenues growth of 4.4% and Adjusted EPS of $0.29. It reaffirmed 2026 constant-currency net revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%.

Financial results
4 source passages
Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC) Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis(1), compared to Q3 2025 Q3 2026 Adjusted EPS(1) of $0.29, an increase of 12% per diluted share Reaffirming full-year 2026 net revenues growth outlook of 5.25% - 6.75% and Adjusted EBITDA growth outlook of 5.75% - 7.25%, both on a constant currency basis Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.23B
Trailing 12 months
Net income (TTM)
$173.47M
Trailing 12 months
Revenue growth YoY
+4.4%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
27.7
Trailing earnings · reciprocal yield 3.6%
FCF yield
2.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.72B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
+3.7%
Trailing year
Short interest
5.8%
Latest settlement · 7.5 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼6.5% $290.20M $12.32M '24 Q4* ▲2.6% $254.52M −$13.26M '25 Q1 ▲6.4% $294.34M $7.96M '25 Q2 ▲9.1% $311.31M $48.40M '25 Q3 ▲4.6% $303.44M $34.85M '25 Q4* ▲10% $280.05M $26.59M '26 Q1 ▲9.2% $321.38M $53.64M '26 Q2 LATEST ▲4.4% $324.89M $58.39M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. Sotera Health reported Q3 revenue, Adjusted EBITDA, Adjusted EPS and sequential Adjusted EBITDA margin growth, strong cash generation, improved leverage and a Moody's upgrade, while reaffirming its 2026 outlook and raising Nelson Labs' growth outlook. Nordion's quarterly declines, Nelson Labs margin contraction, European medical-device softness, flat full-year Adjusted EBITDA margin, a reduced foreign-exchange benefit and ongoing EO litigation remain concerns.

Bullish
  • + Sterigenics delivered 8.2% constant-currency revenue growth and 57 basis points of segment-income-margin expansion.
  • + Nordion expanded its segment-income margin by 71 basis points despite lower revenue. new
  • + Management expects a meaningful step-down in capital expenditures in 2027. new
Bearish
  • − Nordion quarterly revenue declined 11.5% in constant currency and segment income fell 11.4%. new
  • − European medical-device customer softness emerged in the second half of Q3 and continued into early Q4, reducing Sterigenics growth expectations. new
  • − Nelson Labs' segment-income margin declined 199 basis points to 32.1%, primarily because of business mix. new
  • − Full-year Adjusted EBITDA margin is expected to be approximately flat as Nelson Labs margin pressure offsets Sterigenics and Nordion expansion. new
  • − The expected full-year foreign-currency benefit was reduced from 100 basis points to 70 basis points, and Q4 was expected to face a foreign-exchange headwind of more than 100 basis points. new
  • − EO-related litigation continues through scheduled California trials and pretrial proceedings in Illinois, with possible additional claims. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bearish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −2%
below
Price vs 50-day avg −8%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 54%
mid-range
Momentum
relative strength
Neutral
1-month return −7%
trailing
6-month return +4%
trailing
YTD return −6%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $18 › 200d $17 — 50d above 200d
Institutional flow Distributing
278 of 320 funds reported for Sep 30 · net -4.2M sh shares · +52 new
Insider flow Distributing
Net -$21.2M over 90 days · 100% sells
Short interest Rising
5.76% of shares out · ▲ +2.2% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
320 holders — near 3-yr high, broad support
Squeeze score 61
elevated · 0–100
Fundamentals
Strong
Revenue growth +6%
Y/Y
Gross margin 55%
expanding
EPS growth +69%
Y/Y
Free cash flow $149.2M
Valuation P/E 27.7
below peers
Balance sheet $1.8B
net debt
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −32%
past year
ATR 3.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 3
Latest guidance · from the Earnings Call filed Aug 6, 2026
full-year 2026
Constant currency revenue growth Non-GAAP 5.25% – 6.75%
Constant currency adjusted EBITDA growth Non-GAAP 5.75% – 7.25%
Total company revenue Raised $1.24B – $1.25B
Feb 24, 2026 $1.23B – $1.25B changed to Aug 6, 2026 $1.24B – $1.25B
prior FY $1.16B midpoint +7.0% Y/Y
Adjusted EBITDA Non-GAAP Raised $634M – $643M
May 5, 2026 $632M – $641M changed to Aug 6, 2026 $634M – $643M
Interest expense Lowered $135M – $142M
May 5, 2026 $135M – $145M changed to Aug 6, 2026 $135M – $142M
Effective tax rate applicable to adjusted net income Non-GAAP Lowered 27% – 28%
May 5, 2026 27% – 29% changed to Aug 6, 2026 27% – 28%
Adjusted EPS Non-GAAP Raised $0.95 – $1.01
May 5, 2026 $0.93 – $1.01 changed to Aug 6, 2026 $0.95 – $1.01
Capital expenditures Raised $200M – $225M
May 5, 2026 $175M – $225M changed to Aug 6, 2026 $200M – $225M
full year
Total company pricing 3% – 4%
three-year commitment (Investor Day)
Free cash flow $500M – $600M
Previous outlook earlier release · from the Earnings Call filed Aug 8, 2025

Still-open targets the latest release did not restate under the same label.

CapEx · '27 $110M
Guided vs delivered · last 3 settled
Net revenues 2023
guided $1.04B – $1.06B
$1.05B In line
Net revenues 2022
guided $995M – $1.01B
$1B In line
Net revenues full-year 2021
guided $920M – $930M
$931.48M Beat +0.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
−8% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
54% Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $18 › 200d $17 — 50d above 200d
Institutional flow Distributing
278 of 320 funds reported for Sep 30 · net -4.2M sh shares · +52 new
Insider flow Distributing
Net -$21.2M over 90 days · 100% sells
Short interest Rising
5.76% of shares out · ▲ +2.2% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
320 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13 Now $17 · 54% Range high $20
vs 200-day avg -2% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted earnings per share - Basic non-GAAP $0.44 Six Months Ended June 30, 2026 —
Adjusted earnings per share - Diluted non-GAAP $0.44 Six Months Ended June 30, 2026 —
Adjusted EBITDA non-GAAP $621.62M Twelve Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Adjusted Net Income 276.64M
+143.35M Interest expense, net
+102.45M Depreciation
+99.19M Income tax provision applicable to Adjusted Net Income
= Adjusted EBITDA 621.62M
Adjusted EBITDA Margin non-GAAP 51.1% Twelve Months Ended June 30, 2026 —
Adjusted EPS non-GAAP $0.26 Q2 2026 —
Adjusted Net Income non-GAAP $73.96M the three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP Net income (loss) 53.64M
+5.56M Amortization of intangible assets
+7.38M Share-based compensation
+936K Loss on refinancing of debt
-4.27M Gain on foreign currency and derivatives not designated as hedging instruments, net
+1.92M Business optimization expenses
+13.35M Professional services relating to EO sterilization facilities
+0K Illinois EO litigation settlements
+634K Accretion of asset retirement obligations
-5.2M Income tax benefit associated with pre-tax adjustments
= Adjusted Net Income 73.96M
available liquidity 950M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SHC
Sotera Health Co
this stock
$4.74B -5.8% +5.7% 27.7 5.8%
TMO
Thermo Fisher Scientific Inc.
 $259.44B +20.8% +14.5% 36.9 1.3%
DHR
Danaher Corp
 $163.94B +1.8% +8.5% 38.1 1.2%
IDXX
Idexx Laboratories Inc
 $55.48B +4.1% +10.4% 47.5 3.0%
A
Agilent Technologies, Inc.
 $49.04B +27.8% +6.4% 34.2 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
356
% held
101.7%
Reported
278 of 320
Top holder
Sessa Capital IM, L.P.
Held Float
View
Held by Funds
Fund positions
285
View
Short & Settlement
Short Interest Rising
Shares short
16.4M
Days to cover
7.5d
Change
+346.4K sh
View
Short Volume
Short vol %
75%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
7.9K
Value
$145.2K
As of
Sep 24, 2026
View
Off-Exchange
Off-exchange %
29.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$21.2M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$1.2B
Net income (FY)
$77.9M
EPS diluted
$0.27
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 3, 2026
This year
24

Sotera Health reported Q3 2026 net revenues growth of 4.4% and Adjusted EPS of $0.29. It reaffirmed 2026 constant-currency net revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%.

View
Proposed Sales
Value
$2.8M
Shares
150.0K
Filed
Aug 7, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Sotera Health Reports Solid Third…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
SHC +3.8% -7.2% +4.1% -8.5% -5.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +1.2% -6.0% +3.6% -8.3% -16.5%
Key facts CIK 1822479 CUSIP 83601L102 13F (30d) 259 filings 241 filers Visit website Investor relations